Literature DB >> 6323533

A novel electrophoretic variant of human apolipoprotein E. Identification and characterization of apolipoprotein E1.

K H Weisgraber, S C Rall, T L Innerarity, R W Mahley, T Kuusi, C Ehnholm.   

Abstract

A new apolipoprotein E (apo E) phenotype has been demonstrated in a Finnish hypertriglyceridemic subject (R.M.). At the time of this study, R.M.'s plasma triglyceride and cholesterol levels were 1,021 and 230 mg/dl, respectively. The subject's apo E isoelectric focusing pattern was characterized by two major bands, one in the E3 position and the other in the E1 position. Normally the E1 position is occupied by sialylated derivatives of apo E4, E3, or E2. The E1 band of subject R.M. is not a sialylated form, however, because it was not affected by neuraminidase digestion. The identity of the E1 variant as a genetically determined structure was established by amino acid and partial sequence analyses, confirming that the variant is an example of a previously uncharacterized apo E phenotype, E3/1. Both cysteamine modification and amino acid analysis demonstrated that this variant contains two cysteine residues per mole. Sequence analysis of two cyanogen bromide fragments and one tryptic fragment of the apo E3/1 showed that it differs from E2(Arg158----Cys) at residue 127, where an aspartic acid residue is substituted for glycine. This single amino acid interchange is sufficient to account for the one-charge difference observed on isoelectric focusing gels between E2(Arg158----Cys) and the E1 variant. The variant has been designated E1 (Gly127----Asp, Arg158----Cys). When compared with apo E3, the E1 variant demonstrated reduced ability to compete with 125I-LDL for binding to LDL (apo B,E) receptors on cultured fibroblasts (approximately 4% of the amount of binding of apo E3). This defective binding is similar to that of E2-(Arg158----Cys). Therefore, the binding defect of the variant is probably due to the presence of cysteine at residue 158, rather than aspartic acid at residue 127. In contrast, the apo E3 isoform from this subject demonstrated normal binding activity, indicating that it has a normal structure. In family studies, the vertical transmission of the apo E1 variant has been established. It is not yet clear, however, if the hypertriglyceridemia observed in the proband is associated with the presence of the E1(Gly127----Asp, Arg158----Cys) variant.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323533      PMCID: PMC425115          DOI: 10.1172/JCI111287

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  41 in total

1.  Apoprotein (E--A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction.

Authors:  K H Weisgraber; R W Mahley
Journal:  J Biol Chem       Date:  1978-09-10       Impact factor: 5.157

2.  Role of lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts.

Authors:  K H Weisgraber; T L Innerarity; R W Mahley
Journal:  J Biol Chem       Date:  1978-12-25       Impact factor: 5.157

3.  Familial hyperlipoproteinemia type III: deficiency of a specific apolipoprotein (apo E-III) in the very-low-density lipoproteins.

Authors:  G Utermann; M Jaeschke; J Menzel
Journal:  FEBS Lett       Date:  1975-08-15       Impact factor: 4.124

4.  Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man.

Authors:  G Utermann; M Hees; A Steinmetz
Journal:  Nature       Date:  1977-10-13       Impact factor: 49.962

5.  Inhibition of lipoprotein binding to cell surface receptors of fibroblasts following selective modification of arginyl residues in arginine-rich and B apoproteins.

Authors:  R W Mahley; T L Innerarity; R E Pitas; K H Weisgraber; J H Brown; E Gross
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

Review 6.  Lipoprotein structure and metabolism.

Authors:  R L Jackson; J D Morrisett; A M Gotto
Journal:  Physiol Rev       Date:  1976-04       Impact factor: 37.312

Review 7.  The plasma lipoproteins.

Authors:  J C Osborne; H B Brewer
Journal:  Adv Protein Chem       Date:  1977

8.  Lipid transport in liver. I. Electron microscopic identification of very low density lipoproteins in perfused rat liver.

Authors:  R L Hamilton; D M Regen; M E Gray; V S LeQuire
Journal:  Lab Invest       Date:  1967-02       Impact factor: 5.662

9.  Canine lipoproteins and atherosclerosis. I. Isolation and characterization of plasma lipoproteins from control dogs.

Authors:  R W Mahley; K H Weisgraber
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

10.  Radioimmunoassay of arginine-rich apolipoprotein of rat serum.

Authors:  M Fainaru; R J Havel; K Imaizumi
Journal:  Biochim Biophys Acta       Date:  1977-01-25
View more
  14 in total

Review 1.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

2.  The fourth apolipoprotein E haplotype found in the Yoruba of Ibadan.

Authors:  Jill R Murrell; Brandon M Price; Olusegun Baiyewu; Oye Gureje; Mark Deeg; Hugh Hendrie; Adesola Ogunniyi; Kathleen Hall
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2006-06-05       Impact factor: 3.568

3.  Apolipoprotein E2-Christchurch (136 Arg----Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia.

Authors:  M R Wardell; S O Brennan; E D Janus; R Fraser; R W Carrell
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

4.  Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant.

Authors:  S C Rall; Y M Newhouse; H R Clarke; K H Weisgraber; B J McCarthy; R W Mahley; T P Bersot
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  Genotyping of a patient homozygous for a rare apolipoprotein E1 [Gly127-->Asp; Arg158-->Cys] (Weisgraber allele).

Authors:  A Iron; P Richard; M P de Zulueta; G Thomas; M Thomas
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

6.  Human apolipoprotein E expression in Escherichia coli: structural and functional identity of the bacterially produced protein with plasma apolipoprotein E.

Authors:  T Vogel; K H Weisgraber; M I Zeevi; H Ben-Artzi; A Z Levanon; S C Rall; T L Innerarity; D Y Hui; J M Taylor; D Kanner
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  Familial disorders of plasma apolipoproteins.

Authors:  C R Sirtori; G Franceschini
Journal:  Klin Wochenschr       Date:  1985-06-03

8.  Apolipoprotein E4 is deficient in inducing macrophage ABCA1 expression and stimulating the Sp1 signaling pathway.

Authors:  Emmanuel Ugochukwu Okoro; Yanfeng Zhao; ZhongMao Guo; Lichun Zhou; Xinghua Lin; Hong Yang
Journal:  PLoS One       Date:  2012-09-11       Impact factor: 3.240

Review 9.  Role of apolipoprotein E in neurodegenerative diseases.

Authors:  Vo Van Giau; Eva Bagyinszky; Seong Soo A An; Sang Yun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-07-16       Impact factor: 2.570

10.  The relationship between apolipoprotein E gene ε2/ε3/ε4 polymorphism and breast cancer risk: a systematic review and meta-analysis.

Authors:  Yun-Long Liu; Hao-Min Zhang; Hong-Ming Pan; Yu-Hang Bao; Jing Xue; Tian-Chang Wang; Xiao-Cheng Dong; Xiao-Ling Li; Hong-Guang Bao
Journal:  Onco Targets Ther       Date:  2016-03-07       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.